Encouraging news for leukaemia sufferers.
New research could see patients with a rare blood cancer live longer without the side-effects of drugs, doctors say. Chronic myeloid leukaemia (CML) patients are often required to take tyrosine kinase inhibitors (TKIs) indefinitely. But 93% of those in a new study stayed cancer-free after stopping or reducing treatment. Cancer Research UK said the results were "promising" but dosages should not be changed without a doctor's advice.